1. MARFAN SARTAN
Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those <50 kg and 100 mg for those ≥50 kg.
Results
(p = 0.36)
The aortic root diameter increased 0.44 mm/year in the losartan group vs mm/year in the placebo group (p = 0.36)
Mean SBP: 5 mm Hg lower in the losartan group vs. the placebo group (p < 0.05)
Aortic surgery: 9.9% vs. 8.8%, respectively, for losartan vs. placebo
Deaths: 0 vs. 2%, respectively, for losartan vs. placebo
mm/year
0.51
0.44
Conclusions
Among patients with Marfan syndrome, losartan was unable to prevent aortic root dilatation, deaths, or aortic surgery despite a reduction in blood pressure
Losartan
Placebo
Milleron O, et al. Eur Heart J 2015;May 2:[Epub]